Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T17:32:24.701Z.
Calculation as of: 2026-10-06T17:32:24.701Z.
Quote observation: 2026-10-06T16:54:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c2239cca652f31aeacf416f33e6d20b1e6c1b9088f917a2c9fa2f7c7bfc29848
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2014-06-30.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
FREE CASH FLOW YIELD AVG TTM
N/A
FREE CASH FLOW YIELD AVG 3Y
N/A
FREE CASH FLOW YIELD AVG 5Y
N/A
FREE CASH FLOW YIELD AVG 10Y
N/A
FREE CASH FLOW YIELD AVG 15Y
N/A
FREE CASH FLOW YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
InMed Pharmaceuticals Inc.
Market Cap
$7.31M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.07M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$7.59M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$6.98M
Free Cash Flow Yield
N/A
TTM Avg
17.66%
3Y Avg
16.46%
5Y Avg
16.46%
Market Cap
$6.74M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $7.31M | N/A | N/A | N/A | N/A |
| Skye Bioscience, Inc. (SKYE)vs › | $7.31M | N/A | N/A | N/A | N/A |
| Longeveron Inc. (LGVN)vs › | $7.27M | N/A | N/A | N/A | N/A |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.07M | N/A | N/A | N/A | N/A |
| KALA BIO, Inc. (KALA)vs › | $7.03M | N/A | N/A | N/A | N/A |
| Quince Therapeutics, Inc. (QNCX)vs › | $7.59M | N/A | N/A | N/A | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $6.98M | N/A | 17.66% | 16.46% | 16.46% |
| Mangoceuticals, Inc. (MGRX)vs › | $7.00M | N/A | N/A | N/A | N/A |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.74M | N/A | N/A | N/A | N/A |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $6.98M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | FREE CASH FLOW YIELD |
|---|---|
| 2014-06-30 | 0.00% |
| 2014-06-27 | 0.00% |
| 2014-06-26 | 0.00% |
| 2014-06-25 | 0.00% |
| 2014-06-24 | 0.00% |
| 2014-06-23 | 0.00% |
| 2014-06-20 | 0.00% |
| 2014-06-19 | 0.00% |
| 2014-06-18 | 0.00% |
| 2014-06-17 | 0.00% |
| 2014-06-16 | 0.00% |
| 2014-06-13 | 0.00% |
| 2014-06-12 | 0.00% |
| 2014-06-11 | 0.00% |
| 2014-06-10 | 0.00% |
| 2014-06-09 | 0.00% |
| 2014-06-06 | 0.00% |
| 2014-06-05 | 0.00% |
| 2014-06-04 | 0.00% |
| 2014-06-03 | 0.00% |
| 2014-06-02 | 0.00% |
| 2014-05-30 | 0.00% |
| 2014-05-29 | 0.00% |
| 2014-05-28 | 0.00% |
| 2014-05-27 | 0.00% |
| 2014-05-23 | 0.00% |
| 2014-05-22 | 0.00% |
| 2014-05-21 | 0.00% |
| 2014-05-20 | 0.00% |
| 2014-05-19 | 0.00% |
| 2014-05-16 | 0.00% |
| 2014-05-15 | 0.00% |
| 2014-05-14 | 0.00% |
| 2014-05-13 | 0.00% |
| 2014-05-12 | 0.00% |
| 2014-05-09 | 0.00% |
| 2014-05-08 | 0.00% |
| 2014-05-07 | 0.00% |
| 2014-05-06 | 0.00% |
| 2014-05-05 | 0.00% |
